BioLife Solutions
BLFS
38.61
0.00
0.00%
BioLife Solutions
US · BLFS
#2844 by market cap
Listed 1970
38.61
0.00
0.00%
Live - 5344 symbols - heartbeat 482s ago
· 2026-10-07 19:54
- Market cap
- 1.89B
- P/E (TTM)i
- 32.72
- P/Bi
- 4.50
- EPSi
- -0.10
- Div yieldi
- 0.00%
- 52W posi
- 95%
Reader sentiment
Are you bullish or bearish on BLFS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 7 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 101.73% -0.38pp
- Institutions
- 264 +7
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund74.49%
Hedge Fund10.48%
VC/PE Fund9.52%
Public Company3.07%
Individual/Insider2.93%
Government Pension Fund1.53%
Private Company1.15%
Insurance Company1.10%
Sovereign Wealth Fund0.31%
Top holders as of 2026-06-30
BlackRock
13.04% · 6.38M sh
Casdin Capital, LLC
9.52% · 4.66M sh
T. Rowe Price Group, Inc.
7.50% · 3.67M sh
Glazer Capital, LLC
5.49% · 2.69M sh
Vanguard Capital Management, LLC
4.57% · 2.24M sh
Invesco Ltd.
4.45% · 2.18M sh
State Street Global Advisors
3.39% · 1.66M sh
Geode Capital Management, LLC
2.22% · 1.09M sh
MFS Investment Management
2.21% · 1.08M sh
Fred Alger Management, LLC
2.20% · 1.08M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 5 buys · 45 sells
| Name | Role | Stake |
|---|---|---|
| Roderick de Greef | Director | 0.85% |
| Aby Mathew | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | 0.79% |
| Troy Wichterman | Chief Financial Officer | 0.43% |
| Todd Berard | Chief Marketing Officer | 0.33% |
| Rachel Ellingson | Independent Director | 0.12% |
| Joydeep Goswami | Independent Director | 0.11% |
| Sean Werner | Chief Technology Officer | 0.10% |
| Timothy Moore | Independent Director | 0.09% |
| Amy DuRoss | Independent Director | 0.05% |
| Anthony Hunt | Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | Roderick de Greef | Director | Sale to Issuer | -2,775 | $36.69 |
| 2026-09-17 | Aby Mathew | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | Sale to Issuer | -564 | $36.69 |
| 2026-09-17 | Todd Berard | Chief Marketing Officer | Sale to Issuer | -470 | $36.69 |
| 2026-09-17 | Troy Wichterman | Chief Financial Officer | Sale to Issuer | -937 | $36.69 |
| 2026-09-17 | Sean Werner | Chief Technology Officer | Sale to Issuer | -421 | $36.69 |
| 2026-09-07 | Aby Mathew | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | Sale to Issuer | -627 | $35.38 |
| 2026-09-07 | Todd Berard | Chief Marketing Officer | Sale to Issuer | -356 | $35.38 |
| 2026-09-07 | Troy Wichterman | Chief Financial Officer | Sale to Issuer | -1,026 | $35.38 |
| 2026-07-16 | Sean Werner | Chief Technology Officer | Sale to Issuer | -275 | $29.15 |
| 2026-07-06 | Aby Mathew | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | Sale to Issuer | -516 | $27.79 |
| 2026-07-06 | Todd Berard | Chief Marketing Officer | Sale to Issuer | -293 | $27.79 |
| 2026-07-06 | Troy Wichterman | Chief Financial Officer | Sale to Issuer | -844 | $27.79 |
| 2026-06-17 | Roderick de Greef | Director | Sale to Issuer | -2,775 | $26.04 |
| 2026-06-17 | Aby Mathew | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | Sale to Issuer | -564 | $26.04 |
| 2026-06-17 | Todd Berard | Chief Marketing Officer | Sale to Issuer | -470 | $26.04 |
| 2026-06-17 | Troy Wichterman | Chief Financial Officer | Sale to Issuer | -937 | $26.04 |
| 2026-06-17 | Sean Werner | Chief Technology Officer | Sale to Issuer | -420 | $26.04 |
| 2026-06-07 | Aby Mathew | Chairman of Scientific Advisory Board, Executive VP & Chief Scientific Officer | Sale to Issuer | -627 | $26.10 |
| 2026-06-07 | Todd Berard | Chief Marketing Officer | Sale to Issuer | -356 | $26.10 |
| 2026-06-07 | Troy Wichterman | Chief Financial Officer | Sale to Issuer | -1,026 | $26.10 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.